Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cizutamig in Generalized Myasthenia Gravis
NCT07215650Phase 1Recruiting
- Sponsor
- Candid Therapeutics
- Start
- Sep 2025
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cizutamig in myasthenia gravis (MG), sponsored by Candid Therapeutics. Primary endpoints: Incidence and severity of treatment-emergent adverse events at 12 months, Changes from baseline in vital signs at 12 months and 2 more. Started Sep 2025; status: recruiting.
02
Drugs
cizutamig
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT07215650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07215650.